Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$16.28|
|52 Week High||US$4.20|
|52 Week Low||US$38.71|
|1 Month Change||-16.38%|
|3 Month Change||-25.22%|
|1 Year Change||247.86%|
|3 Year Change||-1.69%|
|5 Year Change||n/a|
|Change since IPO||-32.87%|
Recent News & Updates
Our Read On Rubius Therapeutics
Today, we take our first in-depth look at Rubius Therapeutics which has developed a new class of cellular therapies called Red Cell Therapeutics. The company's pipeline has several candidates in development and Rubius recently addressed its current funding needs. A full investment analysis follows in the paragraphs below.
|RUBY||US Biotechs||US Market|
Return vs Industry: RUBY exceeded the US Biotechs industry which returned 17.8% over the past year.
Return vs Market: RUBY exceeded the US Market which returned 31.5% over the past year.
Stable Share Price: RUBY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: RUBY's weekly volatility has decreased from 20% to 8% over the past year.
About the Company
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes.
Rubius Therapeutics Fundamentals Summary
|RUBY fundamental statistics|
Is RUBY overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RUBY income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.94|
|Net Profit Margin||0.00%|
How did RUBY perform over the long term?See historical performance and comparison
Is Rubius Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: RUBY ($16.28) is trading above our estimate of fair value ($10.96)
Significantly Below Fair Value: RUBY is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: RUBY is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: RUBY is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RUBY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RUBY is overvalued based on its PB Ratio (5.5x) compared to the US Biotechs industry average (2.9x).
How is Rubius Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RUBY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RUBY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RUBY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RUBY is forecast to have no revenue next year.
High Growth Revenue: RUBY is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RUBY is forecast to be unprofitable in 3 years.
How has Rubius Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RUBY is currently unprofitable.
Growing Profit Margin: RUBY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RUBY is unprofitable, and losses have increased over the past 5 years at a rate of 34.5% per year.
Accelerating Growth: Unable to compare RUBY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RUBY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: RUBY has a negative Return on Equity (-65.84%), as it is currently unprofitable.
How is Rubius Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: RUBY's short term assets ($304.3M) exceed its short term liabilities ($25.1M).
Long Term Liabilities: RUBY's short term assets ($304.3M) exceed its long term liabilities ($106.9M).
Debt to Equity History and Analysis
Debt Level: RUBY's debt to equity ratio (28.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if RUBY's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RUBY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RUBY has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 36.6% each year.
What is Rubius Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RUBY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RUBY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RUBY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RUBY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RUBY's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pablo Cagnoni (58 yo)
Dr. Pablo J. Cagnoni, M.D., Ph D., is a Director at Turmeric Acquisition Corp. and Repertoire Immune Medicines, Inc. Dr. Cagnoni has been the Chief Executive Officer and Director of Rubius Therapeutics, In...
CEO Compensation Analysis
Compensation vs Market: Pablo's total compensation ($USD3.44M) is about average for companies of similar size in the US market ($USD3.51M).
Compensation vs Earnings: Pablo's compensation has increased whilst the company is unprofitable.
Experienced Management: RUBY's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: RUBY's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.2%.
Rubius Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Rubius Therapeutics, Inc.
- Ticker: RUBY
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.462b
- Shares outstanding: 89.77m
- Website: https://www.rubiustx.com
Number of Employees
- Rubius Therapeutics, Inc.
- 399 Binney Street
- Suite 300
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 23:07|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.